• 1. Embedding cyclic nitrone in mesoporous silica particles for EPR spin trapping of superoxide and other radicals?
  Eric Besson,Stéphane Gastaldi,Emily Bloch,Selma Aslan,Hakim Karoui,Olivier Ouari,Micael Hardy Analyst, 2019,144, 4194-4203
• 2. Evolution in surface coverage of CH3NH3PbI3?XClXvia heat assisted solvent vapour treatment and their effects on photovoltaic performance of devices
  Dhirendra K. Chaudhary,Pramendra Kumar,Lokendra Kumar RSC Adv., 2016,6, 94731-94738
• 3. Empowering microfluidics by micro-3D printing and solution-based mineral coating?
  Hongxia Li,Aikifa Raza,Qiaoyu Ge,Jin-You Lu,TieJun Zhang Soft Matter, 2020,16, 6841-6849
• 4. Fe(iii)-mediated isomerization of α,α-diarylallylic alcohols to ketones via radical 1,2-aryl migration?
  Ziyang Deng,Changwei Chen,Sunliang Cui RSC Adv., 2016,6, 93753-93755
• 5. Evolution of cellulose into flexible conductive green electronics: a smart strategy to fabricate sustainable electrodes for supercapacitors
  Tengfei Yu,Yuehan Wu,Wei Li,Bin Li RSC Adv., 2014,4, 34134-34143

• Solvents and Organic Chemicals Organic Compounds Benzenoids Phenol ethers Anisoles

Benzenecarboximidamide,3,5-dibromo-N-hydroxy-4-methoxy- (CAS No. 31419-81-5): A Comprehensive Overview

Benzenecarboximidamide,3,5-dibromo-N-hydroxy-4-methoxy-, identified by its CAS number 31419-81-5, is a specialized organic compound that has garnered significant attention in the field of pharmaceutical chemistry and bioorganic synthesis. This compound belongs to the class of benzenecarboximidamides, which are characterized by their unique structural and functional properties. The presence of bromine substituents at the 3 and 5 positions, combined with a hydroxyl group at the N position and a methoxy group at the 4 position, endows this molecule with distinct chemical reactivity and potential biological activity.

The synthesis of Benzenecarboximidamide,3,5-dibromo-N-hydroxy-4-methoxy- involves a series of well-defined chemical transformations that highlight the compound's synthetic utility. The introduction of bromine atoms at the 3 and 5 positions enhances its reactivity in various cross-coupling reactions, making it a valuable intermediate in the construction of more complex molecular architectures. The hydroxyl group at the N position further contributes to its versatility, allowing for further functionalization through nucleophilic substitution or condensation reactions.

In recent years, there has been growing interest in exploring the pharmacological potential of benzenecarboximidamides due to their ability to interact with biological targets in novel ways. The structural features of Benzenecarboximidamide,3,5-dibromo-N-hydroxy-4-methoxy-, particularly the presence of bromine and hydroxyl groups, suggest that it may exhibit inhibitory activity against various enzymes and receptors. This has prompted researchers to investigate its potential as a lead compound in drug discovery efforts aimed at developing treatments for diseases such as cancer, inflammation, and neurodegenerative disorders.

One of the most compelling aspects of this compound is its role in the development of novel therapeutic agents. The bromine substituents provide a handle for further chemical modification through palladium-catalyzed cross-coupling reactions, such as Suzuki or Buchwald-Hartwig couplings. These reactions allow for the introduction of aryl or heteroaryl groups at various positions on the benzene ring, expanding the structural diversity of derivatives derived from Benzenecarboximidamide,3,5-dibromo-N-hydroxy-4-methoxy-. Such modifications can fine-tune the pharmacological properties of these derivatives, leading to enhanced potency and selectivity.

The hydroxyl group at the N position also offers opportunities for further functionalization. It can be used to form ether linkages or participate in hydrogen bonding interactions with biological targets. Additionally, the methoxy group at the 4 position can be oxidized to form a hydroxyl group or converted into an azido or alkyne group for further derivatization. These possibilities make Benzenecarboximidamide,3,5-dibromo-N-hydroxy-4-methoxy- a versatile building block for constructing complex molecular entities with tailored biological activities.

Recent studies have demonstrated that benzenecarboximidamides can serve as effective scaffolds for designing molecules with anti-inflammatory properties. The bromine substituents have been shown to enhance binding affinity to certain enzyme targets involved in inflammatory pathways. For instance, derivatives of this compound have been found to inhibit cyclooxygenase (COX) enzymes, which are key players in the production of prostaglandins that mediate inflammation and pain. By modulating these enzymes, such compounds may offer therapeutic benefits in conditions like arthritis and other inflammatory disorders.

The potential application of Benzenecarboximidamide,3,5-dibromo-N-hydroxy-4-methoxy- extends beyond anti-inflammatory therapy. Its structural motif has also been explored in the development of anticancer agents. Preliminary studies suggest that certain derivatives can induce apoptosis in cancer cells by interfering with critical signaling pathways involved in cell survival and proliferation. The ability to modify various functional groups on this scaffold allows researchers to fine-tune its cytotoxicity profile while minimizing off-target effects.

The synthesis and characterization of new derivatives derived from Benzenecarboximidamide,3,5-dibromo-N-hydroxy-4-methoxy- continue to be an active area of research. Advances in synthetic methodologies have enabled the preparation of increasingly complex analogs with enhanced pharmacological properties. Techniques such as high-throughput screening and computational modeling are being employed to identify promising candidates for further development. These efforts are driven by the desire to discover new drugs that address unmet medical needs more effectively than existing therapies.

The future prospects for this compound are promising given its diverse chemical reactivity and potential biological applications. As research progresses, it is likely that new synthetic strategies will be developed to access novel derivatives with improved pharmacokinetic profiles and reduced toxicity. Collaborative efforts between academic researchers and pharmaceutical companies will be essential in translating these findings into tangible therapeutic benefits for patients worldwide.

• 885959-57-9(3-bromo-N'-hydroxy-4-methoxybenzene-1-carboximidamide)
• 1506793-52-7(3-Bromo-2-methoxybenzene-1-carboximidamide)
• 126007-99-6(3-Bromo-4-methoxybenzimidamide hydrochloride)
• 84435-79-0(Benzenecarboximidamide,3,5-dibromo-4-hydroxy-)
• 2102409-98-1(4-BROMO-3-METHOXYBENZIMIDAMIDE HCL)
• 1011264-20-2(4-allyloxy-3-bromo-N-hydroxy-benzamidine)
• 926232-21-5((Z)-3-Bromo-5-ethoxy-N',4-dihydroxybenzene-1-carboximidamide)
• 1799843-56-3(4-Bromo-3-methoxybenzene-1-carboximidamide)
• 1544822-99-2(N-(3-bromo-4-methoxyphenyl)methylhydroxylamine)
• 687985-65-5(3-bromo-4-methoxy-benzamidine)